Turning the Ship
Over the past two years, the FDA’s expectations for eCTD content have been changing rapidly, as evidenced by the volume of new guidances, specifications and advisory documents. Add to that a company’s first-ever submission based on CDISC standards and even large, established pharma companies may find themselves in uncharted territory. It can be like working... Read more »